Santosh S. Waigankar

1.1K posts

Santosh S. Waigankar banner
Santosh S. Waigankar

Santosh S. Waigankar

@sandoc2005

UroOnco & Robotic Surgeon Tech_crazy, love making friends, go-getter Persistent Learner, Researcher, Surgical-Scientist. Prostate Focal Therapy Fellow @ UCLH

Mumbai INDIA & London UK Katılım Aralık 2009
984 Takip Edilen615 Takipçiler
Bruno Nahar
Bruno Nahar@brunonahar·
Happy to have contributed to the latest @ElsevierConnect Hinman’s Atlas of Urologic Surgery! Huge shoutout to @KhandekarArchan for his fantastic work putting it all together— a rising star in our field. Excited to see all the great things he’ll do!
Bruno Nahar tweet mediaBruno Nahar tweet media
English
6
8
70
3.6K
Santosh S. Waigankar
Santosh S. Waigankar@sandoc2005·
🚀 Does More Biopsy = Better Outcomes in Focal Therapy? 🔍 Our #EAU25 study challenges the assumption that higher biopsy sampling density improves recurrence prediction. Findings suggest MRI visibility—not biopsy density—drives patient selection & outcomes.
Santosh S. Waigankar tweet media
English
0
0
4
109
Priyamvada Maitre
Priyamvada Maitre@docpriyamvada·
Speed writing a trial protocol on a Saturday morning 😇 then a guilt-free weekend @MaitreMadan
GIF
English
1
1
18
775
Santosh S. Waigankar
Santosh S. Waigankar@sandoc2005·
@DrGaganGautam It is. AS should not only be patient, but also surgeon driven ! UCLH uses the MEASURED data to counsel patients which include PSAD, max cancer core length, MRI visibility and GS. More the parameters better is the accuracy of the likelihood of being treatment free at 5 yrs.
English
0
0
1
69
Gagan Gautam
Gagan Gautam@DrGaganGautam·
Interesting study on active surveillance in prostate cancer by Bhanji et al...more info for shared decision making with patients eligible for AS!
Gagan Gautam tweet media
English
2
1
9
1.2K
Katie Chan
Katie Chan@channifer·
15 years, 1 husband, 2 babies, 8 house moves, 11 hospitals, 3 cars, 1 fellowship tomorrow I am no longer a “junior doctor” 🙌
Katie Chan tweet media
English
263
374
11.4K
243.7K
Amandeep Arora
Amandeep Arora@dramandeeparora·
One of those “outside of textbook”testicular cancer cases! Left orchidectomy in 2018 -> pure teratoma -> defaulted Now comes with normal markers + L pelvic mass + L scrotal mass + R inguinal mass + nothing in RP We excised all masses & cleared the RPLND template 🤞🏻🤞🏻 1/n
Amandeep Arora tweet mediaAmandeep Arora tweet media
English
3
2
26
2.4K
Prof Veeru Kasi
Prof Veeru Kasi@veerukasi·
Follow the crowd in @birmingham ICC to our exciting @BURSTurology session today at 15.30 Hall 11A on Tuesday @ #BAUS24 on emergency inpatient haematuria and the dilemmas of managing this. #WASHOUT
BURST Urology@BURSTurology

🌟 Our Day 2 at #BAUS24 features "BURST: Emergency Inpatient Haematuria – Time for Change!" 🌟 🕓 15:30: Welcome and Session Introduction 🩸 15:40: Quick Fire MDT on Emergency Haematuria 🕵️‍♂️ 16:25: The WASHOUT Study: Get Involved Now! 📍 Hall 11A #BURSTatBAUS #UroSoMe

English
2
6
23
3.1K
Santosh S. Waigankar
Santosh S. Waigankar@sandoc2005·
Intermediate-risk disease who elected primary PGCA, the five-year freedom-from-failure rate was 91 percent. This includes near- and in-field recurrences 2/3 with int-risk CaP would opt for CRYO over radical surgery.🚨 This is huge 👍🏻☑️ @ibus @usioffice @usiboe @DrRavimohanSM
Perlmutter Cancer Center at NYU Langone Health@Perlmutter_CC

The largest five-year oncological outcomes study for primary partial gland #cryoablation reveals a 91% freedom-from-failure rate in intermediate-risk #prostatecancer. Learn more with study investigators Drs. Herbert Lepor and James Wysock: bit.ly/3WomkHh

English
0
0
2
150